1. 904PImpact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC). (23rd October 2018) Authors: Walker, J; Zajac, M; Ye, J; Scott, M; Ratcliffe, M; Scorer, P; Barker, C; Al-Masri, H; Rebelatto, M C; Gupta, A; Mukhopadhay, P; Ferro, S; Powles, T; Williams, J A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). (23rd October 2018) Authors: Verzoni, E; Ferro, S; Procopio, G; Cova, A; Ratta, R; Raimondi, A; Sepe, P; Squarcina, P; Lalli, L; Huber, V; Rinchai, D; Bedognetti, D; Rivoltini, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗